drugset
drugset / Trial / NCT06394011

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

NCT06394011 ↗

Phase 2 Recruiting 60 enrolled The First Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.

Timeline

Start
2024-02-15
Primary completion
2026-05-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclarubicin Small molecule 10 mg Intravenous
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Cytarabine Small molecule 10 mg/m2 Subcutaneous
Subject Homoharringtonine Small molecule 1 mg Intravenous
Subject Venetoclax Small molecule 400 mg Oral
Background Granulocyte colony-stimulating factor Protein / enzyme biologic 50 ug Subcutaneous
Background Granulocyte colony-stimulating factor Protein / enzyme biologic 300 ug Subcutaneous

Indications

acute myeloid leukemia